|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2002-4-24
|
|
pubmed:abstractText |
Standard multiagent chemotherapy for osteosarcoma may include platinum compounds, doxorubicin, and high-dose methotrexate. By identifying new chemotherapeutic strategies, the outcome of these patients can be improved and the toxicity of treatment regimens decreased.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1077-4114
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
250-5
|
|
pubmed:dateRevised |
2011-10-6
|
|
pubmed:meshHeading |
pubmed-meshheading:11972091-Adolescent,
pubmed-meshheading:11972091-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11972091-Bone Neoplasms,
pubmed-meshheading:11972091-Child,
pubmed-meshheading:11972091-Cyclophosphamide,
pubmed-meshheading:11972091-Dose-Response Relationship, Drug,
pubmed-meshheading:11972091-Etoposide,
pubmed-meshheading:11972091-Female,
pubmed-meshheading:11972091-Humans,
pubmed-meshheading:11972091-Male,
pubmed-meshheading:11972091-Neoplasm Recurrence, Local,
pubmed-meshheading:11972091-Osteosarcoma,
pubmed-meshheading:11972091-Retrospective Studies,
pubmed-meshheading:11972091-Survival Rate,
pubmed-meshheading:11972091-Treatment Outcome
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide.
|
|
pubmed:affiliation |
Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105-2794, USA. carlos.rodriguez-galindo@stjude.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
